ITOS – iteos therapeutics, inc. (US:NASDAQ)
Stock Stats
News
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at Wells Fargo & Company from $19.00 to $17.00. They now have an "overweight" rating on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at JPMorgan Chase & Co. from $22.00 to $15.00. They now have an "overweight" rating on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Form 4 iTeos Therapeutics, Inc. For: Mar 07 Filed by: McGrath Yvonne
Form 4 iTeos Therapeutics, Inc. For: Mar 07 Filed by: Gall Matthew
Form 4 iTeos Therapeutics, Inc. For: Mar 07 Filed by: Call Matthew
Form 4 iTeos Therapeutics, Inc. For: Mar 07 Filed by: Detheux Michel
Form S-8 iTeos Therapeutics, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.